Breaking News Instant updates and real-time market news.

ENDP

Endo

$6.25 /

+0.2 (+3.31%)

18:55
06/11/21
06/11
18:55
06/11/21
18:55

Endo: Tennessee court issues orders regarding state court default judgment

Endo International announced that the Tennessee Court of Appeals recently issued several orders with respect to a default judgment order on liability entered by the Circuit Court for Sullivan County, Tennessee in April 2021 against its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals in Case No. C-41916, originally captioned as Staubus, et al. v. Purdue Pharma, L.P., et al. Specifically, on June 8, 2021, the Tennessee Court of Appeals declined to review the default judgment order on a discretionary basis on the ground that a contempt judgment becomes final upon the entry of punishment and is immediately appealable as of right. Today, the Tennessee Court of Appeals denied without prejudice the plaintiffs' motion to dismiss Endo's separate appeal as of right from the default judgment order and directed Endo to show cause as to why its appeal should not be dismissed on the procedural ground that portions of the default judgment order were not final. The Tennessee Court of Appeals also denied without prejudice Endo's motion to stay further proceedings in the trial court on the procedural ground that Endo must first seek a stay from the trial court. Matthew Maletta, Endo's Executive Vice President and Chief Legal Officer, commented: "As we previously stated, Endo believes the trial court's default judgment order was procedurally, factually and legally deficient. We therefore promptly appealed that order to the Tennessee Court of Appeals. The orders issued today by the Tennessee Court of Appeals do not dispose of Endo's appeal as of right. We will promptly take the actions directed by the Tennessee Court of Appeals and Endo will continue to seek a stay of further trial court proceedings including, if necessary, in the appellate courts." The company also intends to seek review by the Tennessee Supreme Court of the trial court's order permitting the substitution of new plaintiffs in the case after the Tennessee Court of Appeals denied Endo's application for discretionary review of that order on June 8, 2021.

ENDP Endo
$6.25 /

+0.2 (+3.31%)

05/17/21 Citi
Endo price target raised to $11 from $10 at Citi
04/06/21 RBC Capital
Endo transferred with a Sector Perform at RBC Capital
03/08/21 Barclays
Endo price target raised to $7 from $6 at Barclays
03/04/21 Citi
Endo price target lowered to $10 from $11 at Citi

TODAY'S FREE FLY STORIES

Hot Stocks
BeiGene receives China NMPA approval for tislelizumab » 05:21
06/23/21
06/23
05:21
06/23/21
05:21
BGNE

BeiGene

$332.96 /

+7.96 (+2.45%)

BeiGene announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BGNE BeiGene
$332.96 /

+7.96 (+2.45%)

BGNE BeiGene
$332.96 /

+7.96 (+2.45%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BGNE BeiGene
$332.96 /

+7.96 (+2.45%)

  • 02
    Dec
Downgrade
Richemont downgraded to Hold from Buy at HSBC » 05:21
06/23/21
06/23
05:21
06/23/21
05:21
CFRUY

Richemont

$12.35 /

+0.015 (+0.12%)

HSBC analyst Erwan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CFRUY Richemont
$12.35 /

+0.015 (+0.12%)

06/16/21 Societe Generale
Richemont price target raised to CHF 135 from CHF 120 at Societe Generale
06/02/21 Deutsche Bank
Richemont price target raised to CHF 127 from CHF 112 at Deutsche Bank
06/01/21 RBC Capital
Richemont price target raised to CHF 120 from CHF 102 at RBC Capital
05/26/21 Citi
Richemont price target raised to CHF 128 at Citi
Downgrade
Burberry downgraded to Hold from Buy at HSBC » 05:20
06/23/21
06/23
05:20
06/23/21
05:20
BURBY

Burberry

$31.56 /

+0.5 (+1.61%)

HSBC analyst Erwan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BURBY Burberry
$31.56 /

+0.5 (+1.61%)

06/02/21 Exane BNP Paribas
Burberry upgraded to Outperform from Neutral at Exane BNP Paribas
05/14/21 Deutsche Bank
Burberry price target raised to 2,200 GBp from 2,000 GBp at Deutsche Bank
05/14/21 RBC Capital
Burberry price target raised to 2,050 GBp from 2,000 GBp at RBC Capital
03/30/21 UBS
Burberry price target raised to 1,463 GBp from 1,275 GBp at UBS
Downgrade
Hermes downgraded to Reduce from Hold at HSBC » 05:20
06/23/21
06/23
05:20
06/23/21
05:20
HESAY

Hermes

$146.15 /

-0.2425 (-0.17%)

HSBC analyst Erwan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HESAY Hermes
$146.15 /

-0.2425 (-0.17%)

04/23/21 Morgan Stanley
Hermes price target raised to EUR 1,075 from EUR 980 at Morgan Stanley
04/23/21 UBS
Hermes price target raised to EUR 1,146 from EUR 1,079 at UBS
04/23/21 Deutsche Bank
Hermes price target raised to EUR 800 from EUR 760 at Deutsche Bank
04/23/21 JPMorgan
Hermes price target raised to EUR 855 from EUR 755 at JPMorgan
Hot Stocks
Tiziana Life Sciences, FHI Clinical to conduct Foralumab study in Brazil » 05:19
06/23/21
06/23
05:19
06/23/21
05:19
TLSA

Tiziana Life Sciences

$2.33 /

-0.07 (-2.92%)

Tiziana Life Sciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TLSA Tiziana Life Sciences
$2.33 /

-0.07 (-2.92%)

TLSA Tiziana Life Sciences
$2.33 /

-0.07 (-2.92%)

12/22/20 B. Riley Securities
Tiziana Life Sciences initiated with a Buy at B. Riley Securities
TLSA Tiziana Life Sciences
$2.33 /

-0.07 (-2.92%)

Downgrade
Kering downgraded to Hold from Buy at HSBC » 05:19
06/23/21
06/23
05:19
06/23/21
05:19
PPRUY

Kering

$90.98 /

+0.3971 (+0.44%)

HSBC analyst Erwan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PPRUY Kering
$90.98 /

+0.3971 (+0.44%)

05/27/21 RBC Capital
Kering price target raised to EUR 775 from EUR 680 at RBC Capital
05/05/21 Societe Generale
Kering price target raised to EUR 800 from EUR 714 at Societe Generale
04/30/21 Bernstein
Kering upgraded to Outperform from Market Perform at Bernstein
04/22/21 Credit Suisse
Kering price target raised to EUR 695 from EUR 635 at Credit Suisse
PPRUY Kering
$90.98 /

+0.3971 (+0.44%)

PPRUY Kering
$90.98 /

+0.3971 (+0.44%)

Hot Stocks
Enanta reports EDP-721 preclinical data at EASL International Liver Congress » 05:15
06/23/21
06/23
05:15
06/23/21
05:15
ENTA

Enanta

$46.35 /

+0.18 (+0.39%)

Enanta reported new…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ENTA Enanta
$46.35 /

+0.18 (+0.39%)

ENTA Enanta
$46.35 /

+0.18 (+0.39%)

02/09/21 RBC Capital
Enanta price target raised to $53 from $47 at RBC Capital
01/29/21 JPMorgan
Enanta upgraded to Neutral with $55 target at JPMorgan
01/29/21 JPMorgan
Enanta upgraded to Neutral from Underweight at JPMorgan
01/08/21 Piper Sandler
Enanta remains 'significantly undervalued,' says Piper Sandler
ENTA Enanta
$46.35 /

+0.18 (+0.39%)

Upgrade
IMI PLC upgraded to Buy from Hold at HSBC » 05:15
06/23/21
06/23
05:15
06/23/21
05:15
IMIAY

IMI PLC

$47.20 /

+ (+0.00%)

HSBC analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IMIAY IMI PLC
$47.20 /

+ (+0.00%)

06/21/21 JPMorgan
IMI PLC price target raised to 1,750 GBp from 1,650 GBp at JPMorgan
06/18/21 UBS
IMI PLC price target raised to 1,720 GBp from 1,350 GBp at UBS
06/04/21 Credit Suisse
IMI PLC price target raised to 1,900 GBp from 1,700 GBp at Credit Suisse
05/10/21 RBC Capital
IMI PLC price target raised to 1,800 GBp from 1,520 GBp at RBC Capital
General news
FX Action: USD-JPY lifted to its best levels since last Thursday » 05:15
06/23/21
06/23
05:15
06/23/21
05:15
$ECON

Economic Data

/

+

FX Action: USD-JPY lifted…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

Hot Stocks
Hologic receives CE mark for new Aptima CMV Quant assay in Europe » 05:12
06/23/21
06/23
05:12
06/23/21
05:12
HOLX

Hologic

$64.02 /

+0.85 (+1.35%)

Hologic has received CE…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HOLX Hologic
$64.02 /

+0.85 (+1.35%)

HOLX Hologic
$64.02 /

+0.85 (+1.35%)

06/11/21 Citi
Hologic 15% selloff brings 'strong entry point,' says Citi
04/29/21 Citi
Hologic price target lowered to $80 from $90 at Citi
04/05/21 Jefferies
Hologic price target raised to $110 from $106 at Jefferies
02/22/21 BTIG
Hologic price target raised to $91 from $84 at BTIG
HOLX Hologic
$64.02 /

+0.85 (+1.35%)

HOLX Hologic
$64.02 /

+0.85 (+1.35%)

HOLX Hologic
$64.02 /

+0.85 (+1.35%)

HOLX Hologic
$64.02 /

+0.85 (+1.35%)

Hot Stocks
Sosei initiates HTL0022562 trial under Biohaven Pharmaceutical collaboration » 05:10
06/23/21
06/23
05:10
06/23/21
05:10
BHVN

Biohaven Pharmaceutical

$97.19 /

+0.02 (+0.02%)

Sosei Group announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$97.19 /

+0.02 (+0.02%)

BHVN Biohaven Pharmaceutical
$97.19 /

+0.02 (+0.02%)

06/01/21 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $140 from $125 at Cantor Fitzgerald
05/28/21 Mizuho
Biohaven approval should lift 'important overhang,' says Mizuho
05/19/21 Piper Sandler
Piper 'incrementally bullish' on Biohaven, AbbVie migraine drugs
05/12/21 SVB Leerink
Biohaven Pharmaceutical price target lowered to $105 from $115 at SVB Leerink
BHVN Biohaven Pharmaceutical
$97.19 /

+0.02 (+0.02%)

  • 16
    Mar
BHVN Biohaven Pharmaceutical
$97.19 /

+0.02 (+0.02%)

BHVN Biohaven Pharmaceutical
$97.19 /

+0.02 (+0.02%)

Recommendations
Piper 'highly impressed' with Madrigal data in cirrhotic patients » 05:08
06/23/21
06/23
05:08
06/23/21
05:08
MDGL

Madrigal Pharmaceuticals

$102.08 /

-4.42 (-4.15%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$102.08 /

-4.42 (-4.15%)

MDGL Madrigal Pharmaceuticals
$102.08 /

-4.42 (-4.15%)

05/24/21 Piper Sandler
Piper says Madrigal's MAESTRO-NASH outcome not impacted by NGM ALPINE data
05/20/21
Fly Intel: Top five analyst initiations
05/20/21 Goldman Sachs
Madrigal Pharmaceuticals assumed with a Buy at Goldman Sachs
05/18/21 Piper Sandler
Madrigal Pharmaceuticals' new CFO to be 'stellar' player, says Piper Sandler
MDGL Madrigal Pharmaceuticals
$102.08 /

-4.42 (-4.15%)

MDGL Madrigal Pharmaceuticals
$102.08 /

-4.42 (-4.15%)

Hot Stocks
IBM, IISc launch IBM-IISc Hybrid Cloud lab in India » 05:07
06/23/21
06/23
05:07
06/23/21
05:07
IBM

IBM

$146.32 /

-0.32 (-0.22%)

IBM and Indian Institute…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IBM IBM
$146.32 /

-0.32 (-0.22%)

IBM IBM
$146.32 /

-0.32 (-0.22%)

04/20/21 Credit Suisse
IBM price target raised to $165 from $160 at Credit Suisse
04/20/21 Stifel
IBM price target raised to $151 from $147 at Stifel
04/20/21 Morgan Stanley
IBM price target raised to $152 at Morgan Stanley after Q1 results show progress
04/20/21 BMO Capital
IBM price target raised to $150 from $138 at BMO Capital
IBM IBM
$146.32 /

-0.32 (-0.22%)

IBM IBM
$146.32 /

-0.32 (-0.22%)

IBM IBM
$146.32 /

-0.32 (-0.22%)

IBM IBM
$146.32 /

-0.32 (-0.22%)

Hot Stocks
Amgen gets Japanese Ministry of Health, Labour and Welfare approval for Aimovig » 05:05
06/23/21
06/23
05:05
06/23/21
05:05
AMGN

Amgen

$239.96 /

-0.29 (-0.12%)

Amgen announced that the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMGN Amgen
$239.96 /

-0.29 (-0.12%)

AMGN Amgen
$239.96 /

-0.29 (-0.12%)

06/08/21 Citi
Harpoon Therapeutics downgraded to Neutral from Buy at Citi
06/07/21 SVB Leerink
Amgen price target raised to $238 from $230 at SVB Leerink
06/07/21 Oppenheimer
Amgen price target raised to $277 from $272 at Oppenheimer
05/31/21 BMO Capital
Amgen price target raised to $301 from $296 at BMO Capital
AMGN Amgen
$239.96 /

-0.29 (-0.12%)

AMGN Amgen
$239.96 /

-0.29 (-0.12%)

AMGN Amgen
$239.96 /

-0.29 (-0.12%)

AMGN Amgen
$239.96 /

-0.29 (-0.12%)

Recommendations
Par Technology transformation 'remains underappreciated,' says Jefferies » 05:05
06/23/21
06/23
05:05
06/23/21
05:05
PAR

Par Technology

$67.94 /

-0.01 (-0.01%)

Jefferies analyst Samad…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PAR Par Technology
$67.94 /

-0.01 (-0.01%)

PAR Par Technology
$67.94 /

-0.01 (-0.01%)

04/09/21 Craig-Hallum
Par Technology price target raised to $100 from $90 at Craig-Hallum
04/08/21 BTIG
Par Technology price target raised to $110 from $105 at BTIG
04/08/21 Jefferies
Par Technology price target raised to $90 from $75 at Jefferies
03/16/21
Fly Intel: Top five analyst upgrades
PAR Par Technology
$67.94 /

-0.01 (-0.01%)

  • 01
    Oct
PAR Par Technology
$67.94 /

-0.01 (-0.01%)

Hot Stocks
Air Transport Services subsidiary unveils Omni Class cabin configuration » 05:04
06/23/21
06/23
05:04
06/23/21
05:04
ATSG

Air Transport Services

$23.26 /

-0.01 (-0.04%)

, BA

Boeing

$243.78 /

-1.51 (-0.62%)

Omni Air International, a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ATSG Air Transport Services
$23.26 /

-0.01 (-0.04%)

BA Boeing
$243.78 /

-1.51 (-0.62%)

ATSG Air Transport Services
$23.26 /

-0.01 (-0.04%)

06/21/21 Stifel
Air Transport Services resumed with a Buy at Stifel
10/12/20 Loop Capital
Air Transport Services upgraded to Buy from Hold at Loop Capital
BA Boeing
$243.78 /

-1.51 (-0.62%)

06/15/21 Berenberg
Boeing price target raised to $245 from $215 at Berenberg
06/10/21 Jefferies
Boeing shares could move up 5% on China recertification, says Jefferies
06/09/21 Susquehanna
Boeing estimates lowered on light May deliveries, says Susquehanna
06/03/21 Morgan Stanley
Morgan Stanley says recovery tailwinds can offset new launch headwinds at Boeing
ATSG Air Transport Services
$23.26 /

-0.01 (-0.04%)

BA Boeing
$243.78 /

-1.51 (-0.62%)

BA Boeing
$243.78 /

-1.51 (-0.62%)

ATSG Air Transport Services
$23.26 /

-0.01 (-0.04%)

BA Boeing
$243.78 /

-1.51 (-0.62%)

BA Boeing
$243.78 /

-1.51 (-0.62%)

Upgrade
Israel Discount Bank upgraded to Overweight from Equal Weight at Barclays » 05:00
06/23/21
06/23
05:00
06/23/21
05:00
ISDAY

Israel Discount Bank

$48.00 /

+ (+0.00%)

Barclays analyst Tavy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ISDAY Israel Discount Bank
$48.00 /

+ (+0.00%)

03/04/21 Barclays
Israel Discount Bank price target raised to ILS 14.20 at Barclays
01/12/21 Barclays
Israel Discount Bank price target raised to ILS 1,390 from ILS 1,360 at Barclays
Downgrade
Bank Hapoalim downgraded to Equal Weight from Overweight at Barclays » 04:58
06/23/21
06/23
04:58
06/23/21
04:58
BKHYY

Bank Hapoalim

$39.42 /

+ (+0.00%)

Barclays analyst Tavy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BKHYY Bank Hapoalim
$39.42 /

+ (+0.00%)

03/04/21 Barclays
Bank Hapoalim price target raised to ILS 28.60 from ILS 26.30 at Barclays
01/22/21 Citi
Bank Hapoalim upgraded to Buy from Neutral at Citi
01/12/21 Barclays
Bank Hapoalim price target raised to ILS 2,630 from ILS 2,580 at Barclays
07/29/20 Barclays
Bank Hapoalim price target lowered to ILS 2,700 from ILS 2,860 at Barclays
Downgrade
Bank Leumi downgraded to Underweight from Overweight at Barclays » 04:58
06/23/21
06/23
04:58
06/23/21
04:58
BLMIF

Bank Leumi

$7.27 /

-0.73 (-9.13%)

Barclays analyst Tavy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BLMIF Bank Leumi
$7.27 /

-0.73 (-9.13%)

03/04/21 Barclays
Bank Leumi price target raised to ILS 26 from ILS 25 at Barclays
01/12/21 Barclays
Bank Leumi price target raised to ILS 2,500 from ILS 2,410 at Barclays
Upgrade
Parker-Hannifin upgraded to Overweight from Sector Weight at KeyBanc » 04:55
06/23/21
06/23
04:55
06/23/21
04:55
PH

Parker-Hannifin

$289.40 /

+1.33 (+0.46%)

KeyBanc analyst Jeffrey…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PH Parker-Hannifin
$289.40 /

+1.33 (+0.46%)

PH Parker-Hannifin
$289.40 /

+1.33 (+0.46%)

06/11/21 Baird
Parker-Hannifin end markets accelerating growth mode, says Baird
05/05/21 Argus
Parker-Hannifin price target raised to $345 from $310 at Argus
05/03/21 Barclays
Parker-Hannifin price target raised to $340 from $330 at Barclays
04/29/21 Goldman Sachs
Parker-Hannifin price target raised to $369 from $364 at Goldman Sachs
PH Parker-Hannifin
$289.40 /

+1.33 (+0.46%)

Conference/Events
Chemed management to meet virtually with Oppenheimer » 04:55
06/23/21
06/23
04:55
06/23/21
04:55
CHE

Chemed

$480.09 /

+0.69 (+0.14%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CHE Chemed
$480.09 /

+0.69 (+0.14%)

02/25/21 Oppenheimer
Chemed price target lowered to $580 from $600 at Oppenheimer
CHE Chemed
$480.09 /

+0.69 (+0.14%)

Conference/Events
GT Biopharma management to meet virtually with B. Riley » 04:55
06/23/21
06/23
04:55
06/23/21
04:55
GTBP

GT Biopharma

$15.46 /

-1.08 (-6.53%)

Virtual Meetings to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GTBP GT Biopharma
$15.46 /

-1.08 (-6.53%)

GTBP GT Biopharma
$15.46 /

-1.08 (-6.53%)

05/24/21 H.C. Wainwright
GT Biopharma initiated with a Buy at H.C. Wainwright
04/13/21 B. Riley
B. Riley starts GT Biopharma with Buy, sees 101% upside in shares
04/13/21 B. Riley
GT Biopharma initiated with a Buy at B. Riley
03/17/21 Roth Capital
GT Biopharma initiated with a Buy at Roth Capital
  • 11
    Feb
GTBP GT Biopharma
$15.46 /

-1.08 (-6.53%)

Conference/Events
Everbridge participates in a conference call with JPMorgan » 04:55
06/23/21
06/23
04:55
06/23/21
04:55
EVBG

Everbridge

$131.34 /

+1.84 (+1.42%)

Software Analyst Auty…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EVBG Everbridge
$131.34 /

+1.84 (+1.42%)

EVBG Everbridge
$131.34 /

+1.84 (+1.42%)

06/17/21 Stephens
Everbridge assumed with an Overweight at Stephens
03/29/21 Credit Suisse
Everbridge assumed with a Neutral at Credit Suisse
02/19/21 JPMorgan
Everbridge upgraded to Overweight with $200 price target at JPMorgan
02/19/21 Northland
Everbridge price target raised to $165 from $155 at Northland
EVBG Everbridge
$131.34 /

+1.84 (+1.42%)

EVBG Everbridge
$131.34 /

+1.84 (+1.42%)

Conference/Events
Raymond James to hold a virtual conference » 04:55
06/23/21
06/23
04:55
06/23/21
04:55
TFX

Teleflex

$404.93 /

+5.265 (+1.32%)

, CBAY

CymaBay

$4.48 /

-0.26 (-5.49%)

, PYPD

PolyPid

$8.91 /

-0.11 (-1.22%)

, AYLA

Ayala Pharmaceuticals

$11.00 /

+0.3 (+2.80%)

, BWAY

Brainsway

$10.30 /

-0.1 (-0.96%)

, ENTA

Enanta

$46.35 /

+0.18 (+0.39%)

, KDMN

Kadmon

$3.83 /

-0.16 (-4.01%)

, ONCS

OncoSec

$3.40 /

+ (+0.00%)

, ATHA

Athira Pharma

$10.33 /

-0.42 (-3.91%)

, QDEL

Quidel

$111.29 /

-0.5 (-0.45%)

, CYTK

Cytokinetics

$22.15 /

+0.38 (+1.75%)

, NGM

NGM Biopharmaceuticals

$20.37 /

+0.28 (+1.39%)

, MEDXF

Medexus Pharmaceuticals

$5.69 /

-0.06 (-1.04%)

, FLXN

Flexion

$8.86 /

-0.28 (-3.06%)

, HRMY

Harmony Biosciences

$31.17 /

-0.83 (-2.59%)

Human Health Innovation…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TFX Teleflex
$404.93 /

+5.265 (+1.32%)

CBAY CymaBay
$4.48 /

-0.26 (-5.49%)

PYPD PolyPid
$8.91 /

-0.11 (-1.22%)

AYLA Ayala Pharmaceuticals
$11.00 /

+0.3 (+2.80%)

BWAY Brainsway
$10.30 /

-0.1 (-0.96%)

ENTA Enanta
$46.35 /

+0.18 (+0.39%)

KDMN Kadmon
$3.83 /

-0.16 (-4.01%)

ONCS OncoSec
$3.40 /

+ (+0.00%)

ATHA Athira Pharma
$10.33 /

-0.42 (-3.91%)

QDEL Quidel
$111.29 /

-0.5 (-0.45%)

CYTK Cytokinetics
$22.15 /

+0.38 (+1.75%)

NGM NGM Biopharmaceuticals
$20.37 /

+0.28 (+1.39%)

MEDXF Medexus Pharmaceuticals
$5.69 /

-0.06 (-1.04%)

FLXN Flexion
$8.86 /

-0.28 (-3.06%)

HRMY Harmony Biosciences
$31.17 /

-0.83 (-2.59%)

TFX Teleflex
$404.93 /

+5.265 (+1.32%)

05/18/21 Piper Sandler
Teleflex divestiture should accelerate sales growth, says Piper Sandler
05/10/21 Piper Sandler
Teleflex management surprised by post-earnings selloff, says Piper Sandler
04/30/21 SVB Leerink
Teleflex price target raised to $485 from $475 at SVB Leerink
02/25/21 Piper Sandler
Teleflex price target raised to $465 from $405 at Piper Sandler
CBAY CymaBay
$4.48 /

-0.26 (-5.49%)

06/21/21 Piper Sandler
Piper radar 'locked' on CymaBay EASL poster presentations on June 23
06/14/21 JonesTrading
JonesTrading starts CymaBay with Buy, $8 target on seladelpar potential
06/14/21 JonesTrading
CymaBay initiated with a Buy at JonesTrading
06/09/21 Piper Sandler
CymaBay to have 'impressive' lineup at EASL meeting, says Piper Sandler
PYPD PolyPid
$8.91 /

-0.11 (-1.22%)

11/24/20 Raymond James
Raymond James upgrades PolyPid to Strong Buy after BTD for D-PLEX
11/24/20 Raymond James
PolyPid upgraded to Strong Buy from Outperform at Raymond James
08/10/20 Alliance Global Partners
PolyPid initiated with a Buy at Alliance Global Partners
07/21/20 Raymond James
PolyPid initiated with an Outperform at Raymond James
AYLA Ayala Pharmaceuticals
$11.00 /

+0.3 (+2.80%)

12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
12/02/20
Fly Intel: Top five analyst initiations
12/02/20 Noble Capital
Ayala Pharmaceuticals initiated with an Outperform at Noble Capital
BWAY Brainsway
$10.30 /

-0.1 (-0.96%)

04/20/21 Northland
Brainsway initiated with an Outperform at Northland
02/17/21 Raymond James
Brainsway price target raised to $12 from $9 at Raymond James
ENTA Enanta
$46.35 /

+0.18 (+0.39%)

02/09/21 RBC Capital
Enanta price target raised to $53 from $47 at RBC Capital
01/29/21 JPMorgan
Enanta upgraded to Neutral with $55 target at JPMorgan
01/29/21 JPMorgan
Enanta upgraded to Neutral from Underweight at JPMorgan
01/08/21 Piper Sandler
Enanta remains 'significantly undervalued,' says Piper Sandler
KDMN Kadmon
$3.83 /

-0.16 (-4.01%)

06/04/21 Mizuho
Kadmon's KD022 results a positive start for immuno-oncology program, says Mizuho
05/20/21 UBS
Kadmon initiated with a Buy at UBS
03/11/21 Oppenheimer
Kadmon should be bought on weakness from FDA extension, says Oppenheimer
02/10/21 Jefferies
Survey points to 'encouraging' signs for Kadmon's belumosudil, says Jefferies
ONCS OncoSec
$3.40 /

+ (+0.00%)

04/15/21 Alliance Global Partners
OncoSec price target raised to $11 from $6.50 at Alliance Global Partners
03/25/21 Maxim
OncoSec price target raised to $12 from $8 at Maxim
03/08/21
Fly Intel: Top five analyst initiations
03/08/21 BTIG
OncoSec initiated with a Buy at BTIG
ATHA Athira Pharma
$10.33 /

-0.42 (-3.91%)

06/18/21 Jefferies
Athira Pharma's 'unusual situation' to cause some volatility, says Jefferies
06/18/21 Stifel
Athira Pharma CEO leave situation 'impossible to really vet,' says Stifel
06/07/21 JMP Securities
Aducanumab accelerated approval positive for Athira, others, says JMP Securities
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
QDEL Quidel
$111.29 /

-0.5 (-0.45%)

06/17/21 Craig-Hallum
Quidel price target lowered to $219 from $296 at Craig-Hallum
06/04/21 JPMorgan
Quidel price target lowered to $80 from $90 at JPMorgan
05/07/21 JPMorgan
Quidel price target lowered to $90 from $95 at JPMorgan
04/23/21 JPMorgan
Quidel price target lowered to $95 from $120 at JPMorgan
CYTK Cytokinetics
$22.15 /

+0.38 (+1.75%)

05/11/21 Mizuho
Cytokinetics price target raised to $36 from $26 at Mizuho
03/11/21 Wolfe Research
Cytokinetics initiated with an Outperform at Wolfe Research
02/18/21 Barclays
Cytokinetics initiated with an Overweight at Barclays
01/20/21 H.C. Wainwright
Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
NGM NGM Biopharmaceuticals
$20.37 /

+0.28 (+1.39%)

05/25/21 B. Riley
NGM 'disappointing failure' in NASH a 'clearing event,' says B. Riley
05/25/21 BMO Capital
NGM Biopharmaceuticals price target lowered to $20 from $38 at BMO Capital
05/25/21 Raymond James
Raymond James downgrades two NASH players following NGM data
05/24/21 Piper Sandler
Piper says Madrigal's MAESTRO-NASH outcome not impacted by NGM ALPINE data
MEDXF Medexus Pharmaceuticals
$5.69 /

-0.06 (-1.04%)

06/18/21 Canaccord
Medexus Pharmaceuticals price target lowered to C$9 from C$9.50 at Canaccord
03/03/21 Canaccord
Medexus Pharmaceuticals upgraded to Buy from Hold at Canaccord
02/24/21 Stifel
Medexus Pharmaceuticals price target raised to C$17.50 from C$7.25 at Stifel
FLXN Flexion
$8.86 /

-0.28 (-3.06%)

04/26/21 Credit Suisse
Flexion assumed with an Outperform at Credit Suisse
04/14/21 Raymond James
Flexion price target lowered to $16 from $18 at Raymond James
04/06/21 RBC Capital
Flexion transferred with an Outperform at RBC Capital
08/20/20 Goldman Sachs
Flexion initiated with a Neutral at Goldman Sachs
HRMY Harmony Biosciences
$31.17 /

-0.83 (-2.59%)

03/29/21 Goldman Sachs
Harmony Biosciences upgraded to Buy from Neutral at Goldman Sachs
09/14/20 Jefferies
Harmony Biosciences initiated with a Buy at Jefferies
09/14/20 Piper Sandler
Harmony Biosciences initiated with an Overweight at Piper Sandler
09/13/20 Goldman Sachs
Harmony Biosciences initiated with a Neutral at Goldman Sachs
TFX Teleflex
$404.93 /

+5.265 (+1.32%)

CBAY CymaBay
$4.48 /

-0.26 (-5.49%)

PYPD PolyPid
$8.91 /

-0.11 (-1.22%)

AYLA Ayala Pharmaceuticals
$11.00 /

+0.3 (+2.80%)

BWAY Brainsway
$10.30 /

-0.1 (-0.96%)

ENTA Enanta
$46.35 /

+0.18 (+0.39%)

ATHA Athira Pharma
$10.33 /

-0.42 (-3.91%)

QDEL Quidel
$111.29 /

-0.5 (-0.45%)

CYTK Cytokinetics
$22.15 /

+0.38 (+1.75%)

NGM NGM Biopharmaceuticals
$20.37 /

+0.28 (+1.39%)

FLXN Flexion
$8.86 /

-0.28 (-3.06%)

HRMY Harmony Biosciences
$31.17 /

-0.83 (-2.59%)

  • 23
    Feb
  • 21
    Jan
  • 21
    Jan
  • 06
    Jan
  • 18
    Sep
  • 19
    Aug
  • 17
    Jul
  • 26
    Jun
QDEL Quidel
$111.29 /

-0.5 (-0.45%)

KDMN Kadmon
$3.83 /

-0.16 (-4.01%)

ONCS OncoSec
$3.40 /

+ (+0.00%)

ATHA Athira Pharma
$10.33 /

-0.42 (-3.91%)

QDEL Quidel
$111.29 /

-0.5 (-0.45%)

NGM NGM Biopharmaceuticals
$20.37 /

+0.28 (+1.39%)

FLXN Flexion
$8.86 /

-0.28 (-3.06%)

ONCS OncoSec
$3.40 /

+ (+0.00%)

ATHA Athira Pharma
$10.33 /

-0.42 (-3.91%)

Conference/Events
Everest Re to host virtual investor day » 04:55
06/23/21
06/23
04:55
06/23/21
04:55
RE

Everest Re

$244.57 /

+0.94 (+0.39%)

Virtual Investor Day to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RE Everest Re
$244.57 /

+0.94 (+0.39%)

RE Everest Re
$244.57 /

+0.94 (+0.39%)

06/18/21
Fly Intel: Top five analyst downgrades
06/18/21 Citi
Everest Re downgraded to Neutral on valuation at Citi
06/18/21 Citi
Everest Re downgraded to Neutral from Buy at Citi
03/31/21 Citi
Everest Re price target raised to $287 from $275 at Citi
RE Everest Re
$244.57 /

+0.94 (+0.39%)

RE Everest Re
$244.57 /

+0.94 (+0.39%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.